Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-017-0620-7
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9… read more here.
Keywords: clinical pharmacokinetics; evolocumab pcsk9; ldl; pharmacokinetics pharmacodynamics ... See more keywords
Pharmacokinetic and pharmacodynamic effects of two omeprazole formulations on stomach pH and gastric ulcer scores
Sign Up to like & getrecommendations! Published in 2017 at "Equine Veterinary Journal"
DOI: 10.1111/evj.12691
Abstract: REASONS FOR PERFORMING THE STUDY Limited data are available on the relative pharmacokinetics and pharmacodynamics of different omeprazole formulations. OBJECTIVES To compare pharmacokinetic and pharmacodynamic effects of a novel omeprazole formulation against a currently registered… read more here.
Keywords: treatment; pharmacokinetic pharmacodynamic; gastric ulcer; omeprazole formulations ... See more keywords